LakeShore Biopharma Co EBIT

The latest EBIT for YS is $-360M as of March 2024. That is below the sector sector average of $-22M. Investors often review this figure alongside LakeShore Biopharma Co's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, YS currently prints $-360M for EBIT, while the sector average sits near $-22M. That is roughly 1562.9% below the sector mean. Large gaps often invite a closer look at LakeShore Biopharma Co's growth, margins, and balance sheet.

A EBIT figure of $-360M for YS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-22M. Explore the charts below for those layers of context.

After noting YS's EBIT ($-360M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.